Last reviewed · How we verify
AK109
At a glance
| Generic name | AK109 |
|---|---|
| Sponsor | Akeso |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma (PHASE1, PHASE2)
- A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE3)
- A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AK109 CI brief — competitive landscape report
- AK109 updates RSS · CI watch RSS
- Akeso portfolio CI